HLA B*15:02 Carbamazepine Sensitivity HLA Association with Reflex to HLA‑B Typing
Use
HLA‑B*15:02 is associated with an increased risk for carbamazepine‑induced Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Screening before initiation of carbamazepine therapy is recommended, particularly in patients of Asian ancestry, based on FDA‑approved drug labeling and clinical pharmacogenetic guidelines.
Special Instructions
This test includes reflex to HLA‑B typing (high‑resolution) as indicated. The test is being discontinued, and test code 12341‑HLA‑B*15:02 Determination is recommended as the alternative.
Limitations
Not provided.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
8 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL (3 mL minimum)
Minimum Volume
3 mL
Container
EDTA (lavender‑top) tube preferred; acceptable: sodium heparin (green‑top), EDTA (pink‑top), EDTA (royal blue‑top) or sodium citrate (light blue‑top) tube
Collection Instructions
If submitted with any other tests, please submit separate tube for this test. Do not open tube or split sample.
Causes for Rejection
Clotted
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
| Frozen | Unacceptable |